Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.
Location: United States
Employees: 11-50
Total raised: $50M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 16.03.2021 | 3E Biovent... | 3ebiovc.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.10.2025 | Series B | $50M | - |
Mentions in press and media 11
| Date | Title | Description |
| 16.09.2026 | OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody | Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785) and in China (CTR20253261) Fast Track Designation Supports Expedited Development of Cesalatamig for Non-small Cell Lung Cancer (NSCLC) that Pro... |
| 01.09.2026 | OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel | ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as Gen... |
| 17.08.2026 | OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors | — ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, M... |
| 09.04.2026 | OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease | ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2... |
| 27.10.2025 | China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392) | Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited developm... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 13.10.2025 | OncoC4 Secures Nearly $50M Series B for Advanced Clinical Pipeline | OncoC4, a Rockville, MD-based clinical-stage biotechnology company, successfully closed a nearly $50 million Series B funding round. This vital capital infusion drives the accelerated clinical development of its diverse pipeline programs. T... |
| 09.10.2025 | OncoC4: Nearly $50 Million Series B Closed For Clinical Development Plans | OncoC4, a biotechnology company focused on clinical-stage innovations, recently completed a Series B financing round at nearly $50 million. The GBA Fund led this funding round, with contributions from the company’s co-founders and existing ... |
| 02.10.2025 | OncoC4 Raises Nearly $50M in Series B Funding | OncoC4, a Rockville, a MD-based clinical-stage biotechnology company, raised nearly $50M in Series B funding. The round was led by GBA Fund, and supported by additional capital from the company’s co-founders and existing investors, includin... |
| 27.05.2021 | WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership | SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharm... |
Show more